{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:00:00Z","timestamp":1792616400991,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s11060-024-04788-y","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T09:02:57Z","timestamp":1722243777000},"page":"209-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression"],"prefix":"10.1007","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5587-5832","authenticated-orcid":false,"given":"David","family":"Rogawski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meaghan","family":"Roy-O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nova","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Nagpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"4788_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s11912-023-01432-2","volume":"25","author":"MA Roy-O\u2019Reilly","year":"2023","unstructured":"Roy-O\u2019Reilly MA, Lanman T, Ruiz A et al (2023) Diagnostic and therapeutic updates in Leptomeningeal Disease. Curr Oncol Rep 25:937\u2013950. https:\/\/doi.org\/10.1007\/s11912-023-01432-2","journal-title":"Curr Oncol Rep"},{"key":"4788_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","volume":"15","author":"M-J Ahn","year":"2020","unstructured":"Ahn M-J, Chiu C-H, Cheng Y et al (2020) Osimertinib for patients with Leptomeningeal metastases Associated with EGFR T790M-Positive Advanced NSCLC: the AURA Leptomeningeal metastases Analysis. J Thorac Oncol 15:637\u2013648. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.113","journal-title":"J Thorac Oncol"},{"key":"4788_CR3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.19.00457","volume":"38","author":"JCH Yang","year":"2020","unstructured":"Yang JCH, Kim S-W, Kim D-W et al (2020) Osimertinib in patients with epidermal growth factor receptor mutation\u2013positive non\u2013small-cell Lung Cancer and Leptomeningeal metastases: the BLOOM Study. JCO 38:538\u2013547. https:\/\/doi.org\/10.1200\/JCO.19.00457","journal-title":"JCO"},{"key":"4788_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","volume":"15","author":"TM Bauer","year":"2020","unstructured":"Bauer TM, Shaw AT, Johnson ML et al (2020) Brain penetration of Lorlatinib: cumulative incidences of CNS and Non-CNS progression with Lorlatinib in patients with previously treated ALK-Positive non-small-cell Lung Cancer. Targ Oncol 15:55\u201365. https:\/\/doi.org\/10.1007\/s11523-020-00702-4","journal-title":"Targ Oncol"},{"key":"4788_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/JTO.0000000000000455","volume":"10","author":"JF Gainor","year":"2015","unstructured":"Gainor JF, Sherman CA, Willoughby K et al (2015) Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 10:232\u2013236. https:\/\/doi.org\/10.1097\/JTO.0000000000000455","journal-title":"J Thorac Oncol"},{"key":"4788_CR6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jtho.2015.10.010","volume":"11","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Chi AS, Logan J et al (2016) Alectinib Dose Escalation Reinduces Central nervous system responses in patients with anaplastic lymphoma kinase-positive Non-small Cell Lung Cancer Relapsing on Standard Dose Alectinib. J Thorac Oncol 11:256\u2013260. https:\/\/doi.org\/10.1016\/j.jtho.2015.10.010","journal-title":"J Thorac Oncol"},{"key":"4788_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/1759-7714.13259","volume":"11","author":"Z Li","year":"2020","unstructured":"Li Z, Li P, Yan B et al (2020) Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: a case report. Thorac Cancer 11:176\u2013180. https:\/\/doi.org\/10.1111\/1759-7714.13259","journal-title":"Thorac Cancer"},{"key":"4788_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.04.013","volume":"133","author":"E Gaye","year":"2019","unstructured":"Gaye E, Geier M, Bore P et al (2019) Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis. Lung Cancer 133:1\u20133. https:\/\/doi.org\/10.1016\/j.lungcan.2019.04.013","journal-title":"Lung Cancer"},{"key":"4788_CR9","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 F, Park YH, Kim S-B et al (2023) Trastuzumab Deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401:1773\u20131785. https:\/\/doi.org\/10.1016\/S0140-6736(23)00725-0","journal-title":"Lancet"},{"key":"4788_CR10","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"KS-B Cort\u00e9s Javier","year":"2022","unstructured":"Cort\u00e9s Javier KS-B, Wei-Pang C et al (2022) Trastuzumab Deruxtecan versus Trastuzumab Emtansine for breast Cancer. N Engl J Med 386:1143\u20131154. https:\/\/doi.org\/10.1056\/NEJMoa2115022","journal-title":"N Engl J Med"},{"key":"4788_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"J Modi Shanu","year":"2022","unstructured":"Modi Shanu J, William Y, Toshinari et al (2022) Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast Cancer. N Engl J Med 387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"4788_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/neuonc\/noac144","volume":"25","author":"JM P\u00e9rez-Garc\u00eda","year":"2023","unstructured":"P\u00e9rez-Garc\u00eda JM, Vaz Batista M, Cortez P et al (2023) Trastuzumab Deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol 25:157\u2013166. https:\/\/doi.org\/10.1093\/neuonc\/noac144","journal-title":"Neuro Oncol"},{"key":"4788_CR13","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch R, Berghoff AS, Furtner J et al (2022) Trastuzumab Deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med 28:1840\u20131847. https:\/\/doi.org\/10.1038\/s41591-022-01935-8","journal-title":"Nat Med"},{"key":"4788_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41523-023-00519-0","volume":"9","author":"L Alder","year":"2023","unstructured":"Alder L, Trapani D, Bradbury C et al (2023) Durable responses in patients with HER2\u2009+\u2009breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. npj Breast Cancer 9:19. https:\/\/doi.org\/10.1038\/s41523-023-00519-0","journal-title":"npj Breast Cancer"},{"key":"4788_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41523-023-00584-5","volume":"9","author":"N Niikura","year":"2023","unstructured":"Niikura N, Yamanaka T, Nomura H et al (2023) Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and\/or leptomeningeal disease (ROSET-BM). NPJ Breast Cancer 9:82. https:\/\/doi.org\/10.1038\/s41523-023-00584-5","journal-title":"NPJ Breast Cancer"},{"key":"4788_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.cancergen.2011.10.011","volume":"204","author":"JA Mayer","year":"2011","unstructured":"Mayer JA, Pham T, Wong KL et al (2011) FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE\u2122 platform. Cancer Genet 204:589\u2013595. https:\/\/doi.org\/10.1016\/j.cancergen.2011.10.011","journal-title":"Cancer Genet"},{"key":"4788_CR17","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/neuonc\/noac043","volume":"24","author":"E Le Rhun","year":"2022","unstructured":"Le Rhun E, Devos P, Winklhofer S et al (2022) Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort. Neuro Oncol 24:1726\u20131735. https:\/\/doi.org\/10.1093\/neuonc\/noac043","journal-title":"Neuro Oncol"},{"key":"4788_CR18","doi-asserted-by":"publisher","unstructured":"Rhun EL, Weller M, Bent M, van den et al (2023) Leptomeningeal metastasis from solid tumours: EANO\u2013ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101624. ESMO Open 8:","DOI":"10.1016\/j.esmoop.2023.101624"},{"key":"4788_CR19","doi-asserted-by":"publisher","unstructured":"Kumthekar PU, Blouw B, Corkos P et al (2024) The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy. Front Oncol 14. https:\/\/doi.org\/10.3389\/fonc.2024.1402651","DOI":"10.3389\/fonc.2024.1402651"},{"key":"4788_CR20","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jamaoncol.2023.4492","volume":"9","author":"ES Lebow","year":"2023","unstructured":"Lebow ES, Pike LRG, Seidman AD et al (2023) Symptomatic necrosis with antibody-drug conjugates and concurrent stereotactic radiotherapy for Brain metastases. JAMA Oncol 9:1729\u20131733. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4492","journal-title":"JAMA Oncol"},{"key":"4788_CR21","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1200\/JCO.2012.46.5773","volume":"31","author":"N Sch\u00e4fer","year":"2013","unstructured":"Sch\u00e4fer N, Scheffler B, Stuplich M et al (2013) Vemurafenib for Leptomeningeal Melanomatosis. JCO 31:e173\u2013e174. https:\/\/doi.org\/10.1200\/JCO.2012.46.5773","journal-title":"JCO"},{"key":"4788_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/bjc.2017.394","volume":"118","author":"S Nanjo","year":"2018","unstructured":"Nanjo S, Hata A, Okuda C et al (2018) Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. Br J Cancer 118:32\u201337. https:\/\/doi.org\/10.1038\/bjc.2017.394","journal-title":"Br J Cancer"},{"key":"4788_CR23","doi-asserted-by":"publisher","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-20-2081","volume":"26","author":"L Xing","year":"2020","unstructured":"Xing L, Pan Y, Shi Y et al (2020) Biomarkers of Osimertinib Response in patients with refractory, EGFR-T790M-positive Non-small Cell Lung Cancer and Central Nervous System metastases: the APOLLO Study. Clin Cancer Res 26:6168\u20136175. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2081","journal-title":"Clin Cancer Res"},{"key":"4788_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","volume":"18","author":"H-J Stemmler","year":"2007","unstructured":"Stemmler H-J, Schmitt M, Willems A et al (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood\u2013brain barrier. Anticancer Drugs 18:23. https:\/\/doi.org\/10.1097\/01.cad.0000236313.50833.ee","journal-title":"Anticancer Drugs"},{"key":"4788_CR25","doi-asserted-by":"publisher","unstructured":"Remsik J, Tong X, Kunes RZ et al (2023) Leptomeningeal anti-tumor immunity follows unique signaling principles. bioRxiv 20230317533041. https:\/\/doi.org\/10.1101\/2023.03.17.533041","DOI":"10.1101\/2023.03.17.533041"},{"key":"4788_CR26","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele F, Deluche E, Lusque A et al (2023) Trastuzumab Deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med 29:2110\u20132120. https:\/\/doi.org\/10.1038\/s41591-023-02478-2","journal-title":"Nat Med"},{"key":"4788_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y et al (2022) Trastuzumab Deruxtecan in HER2-Mutant non-small-cell Lung Cancer. N Engl J Med 386:241\u2013251. https:\/\/doi.org\/10.1056\/NEJMoa2112431","journal-title":"N Engl J Med"},{"key":"4788_CR28","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"B Shitara Kohei","year":"2020","unstructured":"Shitara Kohei B, Yung-Jue I, Satoru et al (2020) Trastuzumab Deruxtecan in previously treated HER2-Positive gastric Cancer. N Engl J Med 382:2419\u20132430. https:\/\/doi.org\/10.1056\/NEJMoa2004413","journal-title":"N Engl J Med"},{"key":"4788_CR29","doi-asserted-by":"publisher","first-page":"S762","DOI":"10.1016\/j.annonc.2023.09.2354","volume":"34","author":"BT Li","year":"2023","unstructured":"Li BT, Planchard D, Goto K et al (2023) 1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non\u2013small cell lung cancer (NSCLC) with and without brain metastases (BMs): pooled analyses from DESTINY-Lung01 and DESTINY-Lung02. Ann Oncol 34:S762\u2013S763. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2354","journal-title":"Ann Oncol"},{"key":"4788_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","volume":"7","author":"PG Morris","year":"2012","unstructured":"Morris PG, Reiner AS, Szenberg OR et al (2012) Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 7:382\u2013385. https:\/\/doi.org\/10.1097\/JTO.0b013e3182398e4f","journal-title":"J Thorac Oncol"},{"key":"4788_CR31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13014-019-1376-z","volume":"14","author":"W Yan","year":"2019","unstructured":"Yan W, Liu Y, Li J et al (2019) Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis. Radiat Oncol 14:168. https:\/\/doi.org\/10.1186\/s13014-019-1376-z","journal-title":"Radiat Oncol"},{"key":"4788_CR32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/noac195","volume":"25","author":"PU Kumthekar","year":"2023","unstructured":"Kumthekar PU, Avram MJ, Lassman AB et al (2023) A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro Oncol 25:557\u2013565. https:\/\/doi.org\/10.1093\/neuonc\/noac195","journal-title":"Neuro Oncol"},{"key":"4788_CR33","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.22.01148","volume":"40","author":"JT Yang","year":"2022","unstructured":"Yang JT, Wijetunga NA, Pentsova E et al (2022) Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid Tumor Leptomeningeal Metastasis. J Clin Oncol 40:3858\u20133867. https:\/\/doi.org\/10.1200\/JCO.22.01148","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04788-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04788-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04788-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T07:05:10Z","timestamp":1727852710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04788-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["4788"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04788-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients in this study were identified using a retrospective patient registry. The protocol was deemed minimal risk, not requiring consent to participate, and approved by the Stanford University IRB (Protocol ID 70373).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent to participate in this study is not required given it is a retrospective chart review. Consent to publish is not required given there is no identifying information included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"Dr. Nagpal was on the steering committee for FORESEE study of CNSide. The other authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}